29 trends tracked about this subject — the full history, oldest to newest below.
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
Eli Lilly's Zepbound shows promise for knee pain relief alongside weight loss in new Phase 3b data, while Taltz combination therapy demonstrates durable psoriatic arthritis outcomes.
Two case reports describe men who developed psychosis after stopping tirzepatide, adding to questions about the psychiatric effects of discontinuing GLP-1 drugs.
The FDA warns that widely used GLP-1 medications like Ozempic and Zepbound carry a potential risk of vision loss.
Federal regulators mandate new vision loss warning labels across the widely used GLP-1 receptor agonist drug class.
The FDA is requiring all GLP-1 drug makers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.
Federal regulators issue a new warning regarding GLP-1 medications and a rare eye condition linked to sudden blindness.
The FDA is requiring all GLP-1 drug makers to add a warning about NAION, a rare eye condition that can cause sudden blindness, to their prescribing information.
Eli Lilly has struck a deal allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on its platform.
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
19 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
An experimental combination drug from Eli Lilly outperforms Zepbound in a new weight-loss trial.
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Recent studies indicate that popular weight-loss treatments manufactured by Novo Nordisk and Eli Lilly retain efficacy at reduced doses.
New research indicates GLP-1 weight-loss medications like Mounjaro and Zepbound may offer therapeutic benefits for the one billion people with sleep apnea.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Medical experts and news outlets are raising alarms over potential muscle loss and frailty risks associated with GLP-1 weight loss drugs in older populations.
Patients are facing restricted access to GLP-1 drugs like Ozempic and Wegovy due to high costs and restrictive insurance policies.
Medicare initiates a pilot program providing coverage for GLP-1 weight-loss medications beginning July 1, 2026.
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.